Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1410-1416.doi: 10.12092/j.issn.1009-2501.2026.10.012
Yuanyuan ZHENG1,2(
), Yulu BU1,2, Huizhen WU1,2,*(
)
Received:2025-08-19
Revised:2025-09-27
Online:2026-10-26
Published:2026-11-11
Contact:
Huizhen WU
E-mail:ZhengYY_HBMU@163.com;13582005982@163.com
CLC Number:
Yuanyuan ZHENG, Yulu BU, Huizhen WU. Research progress on dotinurad in the treatment of hyperuricemia and gout[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1410-1416.
| Clinical Trial | Phase | Sample Size | Population | Interventions | Outcomes |
| NCT02344875 | Ⅰ | n=24 | Healthy volunteers (stratified by age/sex) | Dotinurad 1 mg (single dose) | PK/PD: No clinically meaningful effects of age/sex. Safety: Well-tolerated. |
| NCT02344862 | Ⅱ | n=80 | Hyperuricemia with/without gout (aged 20-64 years) | Dotinurad (1, 2, 4 mg) vs. Placebo | Efficacy: Significant serum uric acid reduction. Safety: No serious adverse events (AEs) reported. |
| NCT02416167 | Ⅱ | n=200 | Hyperuricemia with/without gout | Dotinurad (0.5, 1, 2, 4 mg) vs. Placebo | Efficacy: Dose-dependent uric acid-lowering effect. Safety: Favorable safety profile with no dose-related increase in AEs. |
| NCT03006445 | Ⅲ | n=330 | Hyperuricemia with/without gout | Dotinurad (2 or 4 mg) | Efficacy: Sustained and sufficient long-term serum uric acid control. Safety: Long-term safety profile confirmed. |
| NCT03100318 | Ⅲ | n=201 | Hyperuricemia with/without gout | Dotinurad (2 mg) vs. Benzbromarone (50 mg) | Efficacy: Non-inferior to benzbromarone in uric acid lowering. Safety: Comparable safety profile. |
| NCT03372200 | Ⅲ | n=203 | Hyperuricemia with/without gout | Dotinurad (2 mg) vs. Febuxostat (40 mg) | Efficacy: Non-inferior to febuxostat in uric acid-lowering effect. Safety: No noteworthy safety concerns. |
Table 1 Major clinical trials’ results of Dotinurad in treatment of Hyperuricemia with/without gout
| Clinical Trial | Phase | Sample Size | Population | Interventions | Outcomes |
| NCT02344875 | Ⅰ | n=24 | Healthy volunteers (stratified by age/sex) | Dotinurad 1 mg (single dose) | PK/PD: No clinically meaningful effects of age/sex. Safety: Well-tolerated. |
| NCT02344862 | Ⅱ | n=80 | Hyperuricemia with/without gout (aged 20-64 years) | Dotinurad (1, 2, 4 mg) vs. Placebo | Efficacy: Significant serum uric acid reduction. Safety: No serious adverse events (AEs) reported. |
| NCT02416167 | Ⅱ | n=200 | Hyperuricemia with/without gout | Dotinurad (0.5, 1, 2, 4 mg) vs. Placebo | Efficacy: Dose-dependent uric acid-lowering effect. Safety: Favorable safety profile with no dose-related increase in AEs. |
| NCT03006445 | Ⅲ | n=330 | Hyperuricemia with/without gout | Dotinurad (2 or 4 mg) | Efficacy: Sustained and sufficient long-term serum uric acid control. Safety: Long-term safety profile confirmed. |
| NCT03100318 | Ⅲ | n=201 | Hyperuricemia with/without gout | Dotinurad (2 mg) vs. Benzbromarone (50 mg) | Efficacy: Non-inferior to benzbromarone in uric acid lowering. Safety: Comparable safety profile. |
| NCT03372200 | Ⅲ | n=203 | Hyperuricemia with/without gout | Dotinurad (2 mg) vs. Febuxostat (40 mg) | Efficacy: Non-inferior to febuxostat in uric acid-lowering effect. Safety: No noteworthy safety concerns. |
| 1 | 中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志, 2020, 36 (1): 1- 13. |
| 2 | Dalbeth N, Gosling AL, Gaffo A, et al. Gout[J]. Lancet, 2021, 397 (10287): 1843- 1855. |
| 3 | Zhang M, Zhu X, Wu J, et al. prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19[J]. Front Immunol, 2022, 12, 791983. |
| 4 | 程伟刚, 李浩林, 杨娟娟, 等. 基于TLR4/Myd88/NF-κB信号通路探讨清热散浊饮治疗高尿酸血症合并痛风性关节炎的作用机制[J]. 中国临床药理学与治疗学, 2025, 30 (4): 456- 463. |
| 5 | Omura K, Miyata K, Kobashi S, et al. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor[J]. Drug Metab Pharmacokinet, 2020, 35 (3): 313- 320. |
| 6 | Xue X, Yuan X, Han L, et al. Effect of clinical typing on serum urate targets of benzbromarone in Chinese gout patients: a prospective cohort study[J]. Front Med (Lausanne), 2022, 8, 806710. |
| 7 | Xu S, Liu X, Ming J, et al. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia[J]. Int J Rheum Dis, 2015, 18 (6): 669- 678. |
| 8 | Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia[J]. Int J Rheum Dis, 2014, 17 (6): 679- 686. |
| 9 | 吴芃, 王亮, 李海涛, 等. 高尿酸血症模型的建立及降尿酸药物的研究进展[J]. 中国病理生理杂志, 2021, 37 (7): 1283- 1294. |
| 10 | Japanese Society of Gout and Nucleic Acid Metabolism. Guideline for the management of hyperuricemia and gout [M]. 3rd ed. Tokyo: Japanese Society of Gout and Nucleic Acid Metabolism, 2019. |
| 11 | Taniguchi T, Ashizawa N, Matsumoto K, et al. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor[J]. J Pharmacol Exp Ther, 2019, 371 (1): 162- 170. |
| 12 | Nakatani H, Fushimi M, Sasaki T, et al. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 8- 16. |
| 13 | Hou Z, Ma A, Mao J, et al. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout[J]. Expert Opin Drug Metab Toxicol, 2023, 19 (12): 895- 909. |
| 14 | Yanai H, Adachi H, Hakoshima M, et al. A possible exquisite crosstalk of urate transporter 1 with other urate transporters for chronic kidney disease and cardiovascular disease induced by dotinurad[J]. Cardiol Res, 2023, 14 (2): 158- 160. |
| 15 | Yanai H, Adachi H, Hakoshima M, et al. A possible therapeutic application of the selective inhibitor of urate transporter 1, dotinurad, for metabolic syndrome, chronic kidney disease, and cardiovascular disease[J]. Cells, 2024, 13 (5): 450. |
| 16 | Hosoya T, Sano T, Sasaki T, et al. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 44- 52. |
| 17 | Hosoya T, Sano T, Sasaki T, et al. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 53- 61. |
| 18 | Hosoya T, Fushimi M, Okui D, et al. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 80- 91. |
| 19 | Furihata K, Nagasawa K, Hagino A, et al. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 36- 43. |
| 20 | Motoki K, Igarashi T, Omura K, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers[J]. Pharmacol Res Perspect, 2019, 7 (6): e00533. |
| 21 | Fukase H, Okui D, Sasaki T, et al. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 17- 24. |
| 22 | Kumagai Y, Sakaki M, Furihata K, et al. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 25- 35. |
| 23 | Omura K, Motoki K, Kobashi S, et al. Identification of human UDP-glucuronosyltransferase and sulfotransferase as responsible for the metabolism of dotinurad, a novel selective urate reabsorption inhibitor[J]. Drug Metab Dispos, 2021, 49 (11): 1016- 1024. |
| 24 | Okui D, Sasaki T, Fushimi M, et al. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 92- 102. |
| 25 | McAdams-DeMarco MA, Maynard JW, Baer AN, et al. A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study[J]. Ann Rheum Dis, 2013, 72 (5): 701- 706. |
| 26 | Takahashi T, Beppu T, Hidaka Y, et al. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials[J]. Clin Exp Hypertens, 2021, 43 (8): 730- 741. |
| 27 | Hosoya T, Sano T, Sasaki T, et al. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 62- 70. |
| 28 | Hosoya T, Furuno K, Kanda S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout[J]. Clin Exp Nephrol, 2020, 24 (Suppl 1): 71- 79. |
| 29 | 朱楠, 侯杰, 李洁, 等. 降尿酸药物别嘌醇、非布司他和苯溴马隆的严重不良反应综述[J]. 中国合理用药探索, 2021, 18 (6): 6- 9. |
| 30 | 曾大勇, 王长连, 黄品芳, 等. 福建汉族人群服用别嘌醇引起严重皮肤不良反应与HLA-B*5801关联性[J]. 中国医院药学杂志, 2015, 35 (12): 1119- 1121. |
| 31 | Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis[J]. Arthritis Care Res, 2012, 64 (10): 1447- 1461. |
| 32 | Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial[J]. Arthritis Rheum, 2008, 59 (11): 1540- 1548. |
| 33 | White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout[J]. N Engl J Med, 2018, 378 (13): 1200- 1210. |
| 34 | Yan F, Xue X, Lu J, et al. Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion[J]. Arthritis Rheumatol, 2022, 74 (12): 2015- 2023. |
| 35 | Zhang MY, Niu JQ, Wen XY, et al. Liver failure associated with benzbromarone: A case report and review of the literature[J]. World J Clin Cases, 2019, 7 (13): 1717- 1725. |
| 36 | Sun P, Zhu JJ, Wang T, et al. Benzbromarone aggravates hepatic steatosis in obese individuals[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (6): 2067- 2077. |
| 37 | Ishikawa T, Takahashi T, Taniguchi T, et al. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout[J]. Expert Opin Pharmacother, 2021, 22 (11): 1397- 1406. |
| [1] | Xiaomian LIU, Ying LIU, Wenjing TU, Shuo ZHANG, Gaoyan ZHU, Yuyan CUI, Xiaoyu CUI, Yixuan YANG, Xiaobing LI, Hongtao GUO, Dong LI, Xiaojuan HE. Unraveling the molecular mechanisms of modified Er-Miao-San (MEMS) in acute gouty arthritis: a multidisciplinary integration of network pharmacology, molecular docking, and experimental validation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 313-323. |
| [2] | WANG Xiaoli, SHAO Jing, ZHANG Wei, TIAN Ping, ZHANG Xuexia, LIU Changhe, LI Kaiyan, YANG Dan, GUO Xiaoyan. Study on the neuroprotective effect and mechanism of Tianma Gouteng Decoction on combining rat model of Hyperactivity of Liver Yang and MCAO based on autophagic flux and CXCL12/CXCR4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1037-1048. |
| [3] | YANG Weidong, WANG Ruiqi, WANG Haihua, YE Tianxiang, CHENG Shenghui, LI Huifang, HAO Xuliang. Flavonoid extract from Dracocephalum rupestre hance in improving gouty arthritis: study based on network pharmacology, molecular docking and animal experiment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(6): 763-773. |
| [4] | CHEN Hongxin, ZHU Lei, HU Jingyi, SHEN Hong. Clinical features of ulcerative colitis complicated with hyperuricemia and the role of hyperuricemia in ulcerative colitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(6): 781-788. |
| [5] | CHENG Weigang, LI Haolin, YANG Juanjuan, BAI Qian, JING Luoyang, HU Lele, JIN Fangmei, WANG Haidong. Qingre sanzhuo decoction treats hyperuricemia complicated with gouty arthritis via TLR4/Myd88/NF-κB signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(4): 456-463. |
| [6] | LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432. |
| [7] | CHEN Yu, GU Bing, LI Huanan. Modulating gut miocrobiota: a new strategy in the treatment of gout [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1307-1314. |
| [8] | GUO Yuting, LI Shanshan, LI Qinglin. Tianma Gouteng Yin protects rotenone-induced PC12 cell damage by inhibiting ferroptosis-lipid metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 8-14. |
| [9] | WU Dan, DIAO Yong, XU Xianxiang. Progress in research on hyperuricemia cell model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 236-240. |
| [10] | YI Hong, GU Bing, CHEN Yunian, LI Huanan. Neutrophil extracellular traps and its role in gouty diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1167-1173. |
| [11] | SUN Shanshan, QU Lianyue, DU Rongrong, LIN Jianyang. Research progress on drug therapy of hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 589-594. |
| [12] | LUO Fei, MEI Yan. Effects of procyanidins on TLR4/NF-κB signaling pathway in rats with acute gouty arthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 41-46. |
| [13] | NA Sha, DUAN Chenfangyuan, WANG Lu, LV Lei, CHEN Guangliang. Effects and mechanism of total saponins of Achyranthes on acute gouty arthritis in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 966-971. |
| [14] | CHEN Guangliang, ZHOU Yuanfeng, ZHANG Ying. Research progress in medicine for treating gout and hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 104-109. |
| [15] | HUANG Xu-hui, SUN Hong, CAI Jia-qin, JU Ming-yu. URAT1 allele 6092(T/C) polymorphism influence uricosuric action of losartan in hyperuricemia patients with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 435-440. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||